Deoxyshikonin decreases cell viability and exhibits anti‐glycolytic activity in acute myeloid leukaemia cells by repressing the glycolytic enzyme pyruvate kinase M2 through inactivation of the Akt/mTOR pathway.23 This evidence concerns the gene AKT1 and acute myeloid leukemia.